08:00 , Nov 24, 2008 |  BC Week In Review  |  Clinical News

Undisclosed intranasal compound: Phase II started

Serenity began a Phase II trial. The compound was developed using the CPE-215 drug delivery technology from CPEX, which spun out from Bentley Pharmaceuticals Inc. (AMEX:BNT, Exeter, N.H.) earlier this year (see BioCentury, July 7)....
07:00 , Aug 18, 2008 |  BC Week In Review  |  Clinical News

Undisclosed intranasal compound: Phase I started

Serenity began a Phase I trial. The compound was developed using the CPE-215 drug delivery technology from CPEX, which spun out from Bentley Pharmaceuticals Inc. (AMEX:BNT, Exeter, N.H.) earlier this year (see BioCentury, July 7)....
07:00 , Aug 11, 2008 |  BC Week In Review  |  Company News

CPEX, Serenity deal

The companies disclosed a September 2007 deal to develop and commercialize an undisclosed compound to treat a urology indication. CPEX used its CPE-215 permeation enhancement technology to develop an intranasal formulation of Serenity’s compound. The...
07:00 , Jul 28, 2008 |  BC Week In Review  |  Company News

Bentley Pharma, Teva deal

Teva completed its previously announced acquisition of Bentley for $14.82 per share, or $360 million in cash. At closing, Bentley consisted solely of its generics business, following the spin-off of its drug delivery business earlier...
07:00 , Jul 7, 2008 |  BC Week In Review  |  Company News

Bentley Pharma drug delivery news

Bentley completed the previously announced spin-out of its drug delivery business into CPEX Pharmaceuticals Inc. The shares of the spin-out began trading July 1 on the NASDAQ under the ticker CPEX. The newco is located...
08:00 , Feb 18, 2008 |  BC Week In Review  |  Clinical News

Nasulin intranasal insulin: Preliminary Phase II data

Preliminary data from an open-label, Indian Phase II trial in 80 Type II diabetes patients receiving oral diabetes drugs showed that Nasulin missed the primary endpoints of a 20 mg/dL reduction in postprandial blood sugar...
08:00 , Nov 19, 2007 |  BC Week In Review  |  Company News

Noven management update

Noven Pharmaceuticals Inc. (NOVN), Miami, Fla.   Business: Drug delivery, Endocrine   Hired: Michael Price as VP and CFO, former VP, CFO, treasurer and secretary at Bentley Pharmaceuticals Inc. ; he replaces Diane Barrett, who...
07:00 , Oct 29, 2007 |  BC Week In Review  |  Company News

Bentley Pharma drug delivery news

BNT will separate its drug delivery and generics businesses. The drug delivery business will spin out into CPEX Pharmaceuticals Inc. , which will trade on NASDAQ under the symbol CPEX. BNT shareholders will own the...
07:00 , Jul 2, 2007 |  BC Week In Review  |  Clinical News

Nasulin intranasal insulin: Interim Phase II data

Interim data from a 4-way crossover U.S. Phase II trial in 12 patients with Type I diabetes showed that Nasulin had faster onset of action than Humalog rapid-acting insulin, Humulin regular insulin or placebo. Nasulin...
07:00 , Apr 23, 2007 |  BC Week In Review  |  Clinical News

Nasulin intranasal insulin: Phase II started

BNT began an Indian Phase II trial of intranasal Nasulin. BNT granted Biocon rights to develop and market the product in Asia, Africa and the Middle East in 2005 (see BioCentury, Nov. 21, 2005). Bentley...